Filtered By:
Source: Gastric Cancer
Cancer: Gastric (Stomach) Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 18 results found since Jan 2013.
Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells
ConclusionsWe clarified the role of galectin-4 in the development of peritoneal dissemination of poorly differentiated gastric cancer cells. Our data highlight the diagnostic and therapeutic potential of galectin-4 in the peritoneal dissemination of gastric cancer.
Source: Gastric Cancer - January 25, 2023 Category: Gastroenterology Source Type: research
Centromeric protein K (CENPK) promotes gastric cancer proliferation and migration via interacting with XRCC5
ConclusionCENPK promotes GC cell proliferation and migration via interacting with XRCC5 and may be a novel prognostic factor or therapeutic target for CENPK.
Source: Gastric Cancer - June 17, 2022 Category: Gastroenterology Source Type: research
The expression of the alpha1 subunit of Na+/K+-ATPase is related to tumor development and clinical outcomes in gastric cancer
ConclusionsATP1A1 appears to regulate tumor progression by altering IFN signaling, and high ATP1A1 expression levels were associated with poor postoperative survival in GC patients. The present results provide novel insights into the function of ATP1A1 as a mediator and/or biomarker of GC.
Source: Gastric Cancer - October 11, 2021 Category: Gastroenterology Source Type: research
LRRC8A influences the growth of gastric cancer cells via the p53 signaling pathway
ConclusionsThe present results indicate that LRRC8A functions as a mediator of and/or biomarker for GC.
Source: Gastric Cancer - August 5, 2021 Category: Gastroenterology Source Type: research
The expression of the alpha1 subunit of Na+/K+-ATPase is related to tumor development and clinical outcomes in gastric cancer
ConclusionsATP1A1 appears to regulate tumor progression by altering IFN signaling, and high ATP1A1 expression levels were associated with poor postoperative survival in GC patients. The present results provide novel insights into the function of ATP1A1 as a mediator and/or biomarker of GC.
Source: Gastric Cancer - July 12, 2021 Category: Gastroenterology Source Type: research
LRRC8A influences the growth of gastric cancer cells via the p53 signaling pathway
ConclusionsThe present results indicate that LRRC8A functions as a mediator of and/or biomarker for GC.
Source: Gastric Cancer - April 16, 2021 Category: Gastroenterology Source Type: research
Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer
ConclusionsOur data indicates that CLK1 plays a crucial role in the regulation of splicing process in gastric cancer and that CLK1 can act as a novel therapeutic target in gastric cancer.
Source: Gastric Cancer - August 20, 2020 Category: Gastroenterology Source Type: research
Inhibition of EZH2 and activation of ERR γ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway
ConclusionThe FOXM1 signaling pathway underlying the ERR γ-mediated gastric cancer suppression was identified. Furthermore, combined treatment with EZH2 inhibitor and ERRγ agonist synergistically suppressed GC progression by inhibiting this signaling pathway, suggesting its high potential in treating GC patients.
Source: Gastric Cancer - June 10, 2020 Category: Gastroenterology Source Type: research
Epstein –Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas
ConclusionsOur findings imply that miR-BART5-5p directly targets PIAS3 and augments PD-L1 through miR-BART5/PIAS3/pSTAT3/PD-L1 axis control. This contributes to antiapoptosis, tumor cell proliferation, invasion and migration, as well as immune escape, furthering gastric carcinoma progression and worsening the clinical outcome, especially in the PD-L1(+) group of patients with EBV-associated gastric carcinomas. miR-BART5-5p may, therefore, be amenable to PD-1/PD-L1 immune checkpoint inhibitor therapy.
Source: Gastric Cancer - March 22, 2020 Category: Gastroenterology Source Type: research
microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2
ConclusionWe found down-regulation of miR-30a in preneoplastic lesions and its tumor-suppressive functions by targetingITGA2 in GC. The level ofITGA2, which functions as an oncogene, was up-regulated in human GC. The results of this study suggest that coordination of the miR-30a-ITGA2 axis may serve as an important mechanism in the development of gastric precancerous lesions and intestinal-type GC.
Source: Gastric Cancer - February 27, 2020 Category: Gastroenterology Source Type: research
Functional analysis and clinical significance of sodium iodide symporter expression in gastric cancer
ConclusionsThese results suggest that NIS regulates tumor progression by affecting IFN signaling, and that its strong expression is related to a worse prognosis in patients with GC. These results provide an insight into the role of NIS as a mediator and/or a biomarker for GC.
Source: Gastric Cancer - September 6, 2018 Category: Gastroenterology Source Type: research
Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells
ConclusionsOur results highlight KRT17 as a possible biomarker in gastric cancer promoting tumor growth, motility, and invasion, and suggest that KRT17 can be a valuable molecular target for development of anti-gastric cancer-specific therapies.
Source: Gastric Cancer - March 14, 2017 Category: Gastroenterology Source Type: research
